Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy

Efficacy of MaaT013:
MaaT Pharma's microbiome-based therapy, MaaT013, has demonstrated unprecedented efficacy in treating steroid-refractory or steroid-dependent gastrointestinal acute graft-versus-host disease (GI-aGvHD), with a gastrointestinal overall response rate (GI-ORR) of 53% at day 281 4.

Survival Rates:
The overall survival rate for responders was significantly higher (81% at day 28 and 67% at 12 months) compared to non-responders (8% at day 28 and 24% at 12 months)1.

Clinical Trial Outcomes:
The Phase 2 HERACLES clinical trial and the Early Access Program (EAP) have shown positive results, with the EAP achieving a GI-ORR of 58% and a 12-month overall survival rate of 38%3 4.

Mechanism of Action:
MaaT013 works by restoring the microbial ecosystem to normalize the immune response, which is crucial in treating acute GvHD3 5.

Precision Nutrition:
Precision nutrition, including probiotics and nutritional supplements, is emerging as a promising approach to modulate the gut microbiota and potentially prevent or revert acute GvHD2.

Importance of Gut Microbiota:
Dysbiosis of the gut microbiota is a significant factor in the development of acute GvHD, and restoring a healthy gut microbiota is critical for improving patient outcomes2 5.